Updated ACR Screening Recommendations on Gadolinium-Based MR Contrast Agents, Renal Disease Patients, and Nephrogenic Systemic Fibrosis (NSF)


The ACR Contrast Committee and the Subcommittee for MR Safety members now recommends, as of July 2007, pre-screening patients prior to the administration of Gadolinium-Based MR Contrast Agents (GBMCA). 

It is recommended that prior to elective Gadolinium Based MR Contrast Agent (GBMCA) administration, a recent (e.g., last 6 weeks) Glomerular Filtration Rate (GFR) assessment be reviewed for patients with a history of:

  1. Renal disease (including solitary kidney, renal transplant, renal tumor)
  2. Age >60
  3. History of Hypertension
  4. History of Diabetes
  5. History of severe hepatic disease/liver transplant/pending liver transplant. For patients in this category only, it is recommended that the patient's GFR assessment be nearly contemporaneous with the MR examination for which the GBMCA is to be administered.